biOasis Technologies Inc
XTSX:BTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
biOasis Technologies Inc
Operating Income
biOasis Technologies Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
biOasis Technologies Inc
XTSX:BTI
|
Operating Income
-CA$3.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Operating Income
-CA$13.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-96%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
$106.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Operating Income
-$373.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-45%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Operating Income
-CA$36.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Operating Income
-$123.2m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
biOasis Technologies Inc
Glance View
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
See Also
What is biOasis Technologies Inc's Operating Income?
Operating Income
-3.1m
CAD
Based on the financial report for Nov 30, 2022, biOasis Technologies Inc's Operating Income amounts to -3.1m CAD.
What is biOasis Technologies Inc's Operating Income growth rate?
Operating Income CAGR 10Y
4%
Over the last year, the Operating Income growth was 14%. The average annual Operating Income growth rates for biOasis Technologies Inc have been 23% over the past three years , 1% over the past five years , and 4% over the past ten years .
